title: Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease.
abstract: BACKGROUND
  There is evidence that fat mass is correlated with bone mineral density (BMD) in inflammatory bowel disease (IBD), but data on the role of adipokines on this association are limited. The aim of this study was to investigate the serum levels of chemerin, visfatin, and vaspin, hormones that act as adipokines, in relation to BMD in patients with ulcerative colitis (UC) and Crohn's disease (CD).
  
  
  METHODS
  Serum from 120 IBD patients (68 CD, 52 UC) and 98 matched healthy controls (HC) was collected. Chemerin, visfatin, and vaspin levels were assessed using an enzyme-linked immunosorbent assay. BMD was determined for the lumbar spine and the proximal femur using dual-energy X-ray absorptiometry. Full-body composition scans were analyzed using enCORE software based on the absorptiometry system.
  
  
  RESULTS
  Serum chemerin was higher in IBD patients than HC [CD 13.67.1±5.8, UC 13.9±4.3 vs. HC 7.8±2.6 ng/ml, odds ratio (OR): 0.95, 95% confidence interval (CI) 0.93-0.98, P<0.0001]. Serum visfatin levels in CD patients were significantly higher than those in UC patients (9.3±14.01 vs. 6.5±7.2 ng/ml, OR: 0.86, 95% CI 0.80-0.92, P=0.039). In multivariate logistic regression analysis, a significant independent association of osteoporosis (T-score ≤2.5 SD) with age (OR: 1.04, 95% CI 1.01-1.08, P=0.02), visfatin (OR: 0.78, 95% CI 0.63-0.97, P=0.02), and chemerin levels (OR: 0.83, 95% CI 0.70-0.98, P=0.03), but not with BMI or body composition, was found.
  
  
  CONCLUSIONS
  Serum visfatin and chemerin levels are associated with the development of osteoporosis in IBD. These results suggest a role of visfatin and chemerin in the pathophysiology of osteoporosis in IBD.
authors.affiliation: Departments of aGastroenterology bMedical Physics cLaboratory of Biochemistry, University Hospital of Heraklion, Crete, Greece.
authors.forename: Sotirios
authors.initials: S
authors.lastname: Terzoudis
authors.forename: Niki
authors.initials: N
authors.lastname: Malliaraki
authors.forename: John
authors.initials: J
authors.lastname: Damilakis
authors.forename: Daphne A
authors.initials: DA
authors.lastname: Dimitriadou
authors.forename: Christos
authors.initials: C
authors.lastname: Zavos
authors.forename: Ioannis E
authors.initials: IE
authors.lastname: Koutroubakis
mesh_terms: D015502:Absorptiometry, Photon; D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001823:Body Composition / Q000502:physiology; D015519:Bone Density / Q000502:physiology*; D016022:Case-Control Studies; D018925:Chemokines / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D005272:Femur Neck / Q000503:physiopathology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D008159:Lumbar Vertebrae / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D010024:Osteoporosis / Q000097:blood / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D015843:Serpins / Q000097:blood
chemical_list: D054392:Adipokines; D015415:Biomarkers; D018925:Chemokines; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; C478630:RARRES2 protein, human; C507339:SERPINA12 protein, human; D015843:Serpins; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human